Evernest Financial Advisors LLC Buys 20 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Evernest Financial Advisors LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 521 shares of the medical research company’s stock after purchasing an additional 20 shares during the quarter. Evernest Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $271,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in TMO. Quarry LP raised its position in Thermo Fisher Scientific by 86.2% in the second quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after acquiring an additional 56 shares during the period. Brown Financial Advisors bought a new stake in Thermo Fisher Scientific during the second quarter valued at about $671,000. Heritage Wealth Management Inc. bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $334,000. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Thermo Fisher Scientific by 0.4% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 68,321 shares of the medical research company’s stock valued at $37,782,000 after buying an additional 264 shares in the last quarter. Finally, Centaurus Financial Inc. increased its holdings in Thermo Fisher Scientific by 3.3% in the 2nd quarter. Centaurus Financial Inc. now owns 6,283 shares of the medical research company’s stock worth $3,475,000 after acquiring an additional 201 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Scotiabank started coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective on the stock. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Finally, Bank of America dropped their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $607.06 on Friday. The firm has a 50-day moving average of $537.83 and a two-hundred day moving average of $570.33. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The stock has a market cap of $232.20 billion, a price-to-earnings ratio of 38.06, a price-to-earnings-growth ratio of 3.89 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 9.78%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 29,000 shares of company stock worth $15,859,540 in the last three months. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.